CAMP4 Reports Full Year 2024 Financial Results and Provides Corporate Update

Core Insights - CAMP4 Therapeutics is advancing its clinical programs, particularly focusing on CMP-CPS-001 for Urea Cycle Disorders (UCDs) and has initiated a Phase 1b trial for female OTC heterozygotes, addressing an underserved patient population [2][3][11] - The company has nominated CMP-SYNGAP-01 as a development candidate for SYNGAP1-related disorders, with promising preclinical data supporting its potential [2][11] - Financial results for the year ended December 31, 2024, show a net loss of $51.8 million, with cash and cash equivalents of approximately $64.0 million, sufficient to fund operations into Q2 2026 [6][7][8] Clinical Development - The Phase 1 clinical trial of CMP-CPS-001 in UCDs is ongoing, with dosing completed in two of four multiple ascending dose cohorts, and safety data expected in Q4 2025 [1][4] - The planned expansion into a Phase 1b clinical trial in female OTC heterozygotes is anticipated to begin in Q2 2025, with a Clinical Trial Application (CTA) to be submitted in Europe [2][11] - Recent studies indicate that female carriers of OTC deficiency may experience significant health risks, prompting a shift from passive observation to proactive treatment [3][11] Financial Performance - Research and development expenses for 2024 were $38.8 million, a decrease from $40.6 million in 2023, primarily due to reduced clinical and preclinical costs [6] - General and administrative expenses increased to $14.9 million in 2024 from $11.6 million in 2023, attributed to higher personnel-related costs [7] - The company reported a net loss of $51.8 million for 2024, compared to a loss of $49.3 million in 2023, with a net loss per share of $11.04 [7][15] Cash Position - As of December 31, 2024, CAMP4 had cash and cash equivalents of approximately $64.0 million, which is expected to support its planned activities into Q2 2026 [8][15] - The company’s total assets increased to $78.3 million in 2024 from $54.9 million in 2023, while total liabilities decreased slightly [15] Strategic Initiatives - CAMP4 is focusing on expanding its strategic partnerships to enhance the value of its RAP Platform, which targets regulatory RNAs to amplify gene expression [11] - The company has initiated a discovery program for GBA1-related Parkinson's Disease, with ongoing preclinical studies to identify a development candidate [11]